Cytek Biosciences initiated with bullish view at Stephens, here’s why

Stephens initiated coverage of Cytek Biosciences with an Overweight rating and $9 price target. The analyst views Cytek’s full spectrum technology as “differentiated” and believes the performance advantages of its platforms are compelling to customers in higher-growth segments of the cell analysis market. Cytek has consistently outgrown the broader cell analysis market while maintaining a disciplined approach to costs, making it one of the few small cap tools names with positive adjusted EBITDA, the analyst tells investors in a research note.